Fosaprepitant Dimeglumine, Injection | ||||
CAS NO.: | 265121-04-8 | |||
Chemical Formula: | C37H56F7N6O16P | |||
Molecular Weight: | 1004.8000 | |||
DMF&GMP status: | Please contact us for more details. | Description: |
Mechanism of Action
Fosaprepitant is a prodrug of aprepitant and accordingly, its antiemetic effects are attributable to aprepitant. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CINV). Aprepitant has been shown in animal models to inhibit emesis induced by cytotoxic chemotherapeutic agents, such as cisplatin, via central actions. Animal and human Positron Emission Tomography (PET) studies with aprepitant have shown that it crosses the blood brain barrier and occupies brain NK1 receptors. Animal and human studies have shown that aprepitant augments the antiemetic activity of the 5-HT3-receptor antagonist ondansetron and the corticosteroid dexamethasone and inhibits both the acute and delayed phases of cisplatin-induced emesis. **Please noted, we do not sell medicines to Individuals. Our products are for Pharmaceutical Companies, Wholesalers, Research Organization and Institutes. A safe online Medicine store should have License by the state board of pharmacy, have a licensed pharmacist, require a prescription and more. For instructions about how to purchase the medicines online, please review FDA official website. |
|
Approvals | ||||
Active Ingredient | Dosage Form; Route | Strength | Proprietary Name | Applicant |
FOSAPREPITANT DIMEGLUMINE | POWDER;INTRAVENOUS | Please contact us for more details | Please contact us for more details | Please contact us for more details |
Patent Data | ||||
Patent No. | Patent Expiration | Drug Substance Claim | Drug Product Claim | Patent Use Code |
N.A. | N.A. | N.A. | N.A. | N.A. |
Exclusive Data | ||||
Exclusivity Code | Exclusivity Expiration | |||
N.A. | N.A. | |||